European Society for Medical Oncology Congress (ESMO)

Andrew Armstrong, MD, MSc, spoke about key findings, patient crossover, and takeaways from the ARCHES trial for metastatic hormone-sensitive prostate cancer.

Ravi A. Madan, MD, discusses the potential impact of docetaxel, abiraterone acetate, androgen deprivation therapy, and radiotherapy on patients with metastatic castration-sensitive prostate cancer.

Men with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy experienced an improved, long-lasting overall survival compared with those who received placebo.

Solange Peters, MD, PhD, detailed several important abstracts from the Presidential Symposia at the 2021 ESMO Congress she believes will be practice changing.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk about key findings observed when utilizing cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer.

Marshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.

ESMO’s president, Solange Peters, MD, PhD, discussed a handful of key abstracts presented during the 3 Presidential Symposia sessions at the 2021 ESMO Congress.

Final read-out of progression-free survival data from the ALTA-1L trial indicates significant benefit of brigatinib versus crizotinib for patients with ALK-positive non–small cell lung cancer who have not previously received an ALK inhibitor.

Acceptable safety was noted with the addition of darolutamide to androgen deprivation therapy and resulted in infrequent extra adverse effects versus placebo in men with nonmetastatic castration-resistant prostate cancer.

Ravi Madan, MD, discusses clinical findings utilizing PET imaging and Tc99 scans in patients with metastatic castration-resistant prostate cancer who are being treated with enzalutamide

CancerNetwork® sat down with David O’Malley, MD, at the 2021 European Society for Medical Oncology to talk about the OReO trial and how these findings impact what’s already known about PARP inhibitors for the treatment of ovarian cancer.

CancerNetwork® spoke with Michael Schweizer, MD, at the 2021 ESMO Congress about his research into the combination of olaparib plus bipolar androgen therapy for patients with castration-resistant prostate cancer.

A phase 2 trial did not find a significant benefit to progression-free survival with regorafenib in patients with advanced or metastatic chrodoma.

Findings from the PACIFIC-R trial indicated that the real-world progression-free survival benefit of durvalumab was higher vs the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in unresectable stage III non–small cell lung cancer.

An association was seen between baseline HER2 expression levels and the antitumor activity of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive, metastatic colorectal cancer.

CancerNetwork® sat down with Jason Luke, MD, at the 2021 European Society for Medical Oncology Congress to talk about the latest developments in the use of immunotherapy for metastatic disease.

Adavosertib demonstrated a 65% risk reduction in disease progression and death for patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

Patients with extensive-stage small cell lung cancer (ES-SCLC) derived overall survival benefit from a combination of durvalumab and chemotherapy.

Consistent Ki67 suppression with giredestrant was noted in a phase 2 trial versus anatrozole.

Patients with advanced non–small cell lung cancer receiving sitravatinib plus nivolumab combination had promising objective responses during a post-hoc analysis of a phase 2 trial.

Patient with advanced renal cell carcinoma who were treated with nivolumab and ipilimumab experienced a long-term survival benefit that was superior to sunitinib.

According to results from the Blood First Assay Screening Trial, blood-based tumor mutational burden did not predict a benefit of atezolizumab over chemotherapy for patients with non-small cell lung cancer.

Investigators believe the use of biomarkers can determine the results of de-escalated neoadjuvant T-DM1 in HR-positive/HER2-positive early breast cancer.

Patients with stage II to IIIA non–small cell lung cancer experienced an improvement in disease-free survival and time to locoregional and distant relapse after being treated with adjuvant atezolizumab.

Treatment with sunitinib resulted in improved efficacy results in the FIRSTMAPPP trial for patients with malignant pheochromocytoma and paraganglioma.

Results of a single-arm study indicate that patients with previously treated metastatic cervical cancer may derive benefit from treatment with balstilimab plus zalifrelimab.

Data from the Circulating Cell-Free Genome Atlas on Clinical limit of detection, or cLOD, may help investigators better detect multiple cancers at earlier stages.

Examination of tisotumab vedotin plus key standard-of-care therapeutics shows promise for the treatment of cervical cancer in the frontline setting and beyond.

Overall survival in patients with de novo metastatic castration-sensitive prostate cancer improves with addition of prednisone and abiraterone to androgen-deprivation therapy plus docetaxel.

Data presented at 2021 ESMO show that nivolumab plus chemotherapy improves survival outcomes in certain patients with frontline gastrointestinal cancers, but not nivolumab plus ipilimumab.